Enzyvant
Dr. Blair McNeill leads all aspects of CMC at Enzyvant, including process development, analytical development, external development, and clinical and commercial manufacturing. Additionally, Dr. McNeill is responsible for global strategic alignments with Sumitomo Pharma’s regenerative medicine division.
Dr. McNeill brings over 25 years of development and manufacturing experience in complex biologics from multiple startups and pharmaceutical companies including Amgen, Bayer and Alkermes. Prior to his position at Enzyvant, Dr. McNeill served as Senior Vice President and Head of CMC for Sumitovant Biopharma, where he provided guidance and technical leadership spanning from initial development to commercialization, across five subsidiary organizations.
Dr. McNeill holds a Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University.
Enzyvant
Enzyvant is a clinical stage biopharmaceutical company with an initial therapeutic focus in pulmonary arterial hypertension.